References
- Godfrey D, Hammond K, Poulton L, Baxter A. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573–583
- Wilson M T, Singh A K, Kaer L. Immunotherapy with ligands of natural killer T cells. Trends Mol Med 2002; 8: 225–231
- Swann J, Crowe N Y, Hayakawa Y, Godfrey D I, Smyth M J. Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunol Cell Biol 2004; 82: 323–331
- Carnaud C, Lee D, Donnars O, Park S H, Beavis A, Koezuka Y, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163: 4647–4650
- van der Vliet H JJ, Molling J W, von Blomberg B ME, Nishi N, Kolgen W, van den Eertwegh A JM, et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004; 112: 8–23
- Takahashi T, Nieda M, Koezuka Y, Nicol A, Porcelli S A, Ishikawa Y, et al. Analysis of human Vα24+ CD4+ NKT cells activated by α- glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000; 164: 4458–4464
- Metelitsa L S, Naidenko O V, Kant A, Wu H W, Loza M J, Perussia B, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001; 167: 3114–3122
- Gansuvd B, Hagihara M, Yu Y, Inoue H, Ueda Y, Tsuchiya T, et al. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms. Hum Immunol 2002; 63: 164–175
- Takahashi T, Haraguchi K, Chiba S, Yasukawa M, Shibata Y, Hirai H. Vα24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy. Br J Haematol 2003; 122: 231–239
- Metelitsa L S, Weinberg K, Emanuel P, Seeger R C. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003; 17: 1068–1077
- Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, Schudeletti M, et al. CD1d is expressed on B-chronic lymphoblastic leukemia cells and mediates a-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 2004; 109: 402–411
- Zhou D, Mattner J, Cantu C, III, Schrantz N, Yin N, Gao Y, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004; 306: 1786–1789
- Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188: 1521–1528
- Giaccone G, Punt C JA, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand α- galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8: 3702–3709
- Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103: 383–389
- Moodycliffe A, Nghiem D, Clydesdale G, Ullrich S. Immune suppression and skin cancer development: regulation by NKT cells. Nature Immunol 2000; 1: 521–525